Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc. T.MBX

Alternate Symbol(s):  MBXBF

Healthcare Biotechnology
Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.


TSX:MBX - Post by User

Microbix Biosystems Inc. > Q1 2021 Results
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(10)
•••
Comment by ssdasmmon Feb 11, 2021 3:28pm
83 Views
Post# 32543468

RE:RE:RE:RE:RE:RE:RE:Q1 2021 Results

RE:RE:RE:RE:RE:RE:RE:Q1 2021 ResultsGood point, on earlier posts, I was always more focused on a record Q1, then a record Q2 and so on. based on cameron's guidance, That is where I will stay, looking forward to tomorrows call.  

Q1 revenue was $3,157,659, a 54% increase from Q1 2020

Q2?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities